{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wallace MJ"],"funding":["National Institute of Allergy and Infectious Diseases","NIAID NIH HHS","American Lebanese Syrian Associated Charities","St. Jude Children&apos;s Research Hospital"],"pagination":["467-478"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7477787"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["6(3)"],"pubmed_abstract":["Increasing rates of drug-resistant Gram-negative (GN) infections, combined with a lack of new GN-effective antibiotic classes, are driving the need for the discovery of new agents. Bacterial metabolism represents an underutilized mechanism of action in current antimicrobial therapies. Therefore, we sought to identify novel antimetabolites that disrupt key metabolic pathways and explore the specific impacts of these agents on bacterial metabolism. This study describes the successful application of this approach to discover a new series of chemical probes, <i>N</i>-(phenyl)thioacetamide-linked 1,2,3-triazoles (TAT), that target cysteine synthase A (CysK), an enzyme unique to bacteria that is positioned at a key juncture between several fundamental pathways. The TAT class was identified using"],"journal":["ACS infectious diseases"],"pubmed_title":["Discovery and Characterization of the Antimetabolite Action of Thioacetamide-Linked 1,2,3-Triazoles as Disruptors of Cysteine Biosynthesis in Gram-Negative Bacteria."],"pmcid":["PMC7477787"],"funding_grant_id":["R01 AI136803","R01AI136803"],"pubmed_authors":["Wright WC","Yao J","Phelps GA","Reeve SM","Lee RE","Lee RB","Wallace MJ","Gee CT","Dharuman S","Elmore JM","Fernando DM","Griffith EC","Chen T"],"additional_accession":[]},"is_claimable":false,"name":"Discovery and Characterization of the Antimetabolite Action of Thioacetamide-Linked 1,2,3-Triazoles as Disruptors of Cysteine Biosynthesis in Gram-Negative Bacteria.","description":"Increasing rates of drug-resistant Gram-negative (GN) infections, combined with a lack of new GN-effective antibiotic classes, are driving the need for the discovery of new agents. Bacterial metabolism represents an underutilized mechanism of action in current antimicrobial therapies. Therefore, we sought to identify novel antimetabolites that disrupt key metabolic pathways and explore the specific impacts of these agents on bacterial metabolism. This study describes the successful application of this approach to discover a new series of chemical probes, <i>N</i>-(phenyl)thioacetamide-linked 1,2,3-triazoles (TAT), that target cysteine synthase A (CysK), an enzyme unique to bacteria that is positioned at a key juncture between several fundamental pathways. The TAT class was identified using","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Mar","modification":"2026-05-01T05:59:17.713Z","creation":"2021-03-16T08:15:02Z"},"accession":"S-EPMC7477787","cross_references":{"pubmed":["31887254"],"doi":["10.1021/acsinfecdis.9b00406"]}}